載入...
Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment
AIMS: The aim of this study was to develop a population pharmacokinetic (PK) model of udenafil and its active metabolite, DA‐8164, in healthy subjects and patients with hepatic impairment (HI) and to estimate the optimal dosing recommendations for patients with HI. METHODS: An open label, three para...
Na minha lista:
| 發表在: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4972155/ https://ncbi.nlm.nih.gov/pubmed/27084997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12977 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|